CDKN2A and neoplasm: Among validated alterations across all the samples, TP53, PIK3CA, KRAS, ESR1 and CDKN2A/B were the most frequently altered genes, which is in accordance with the tumour types screened, as the majority were metastatic breast, colon and pancreas cancers [41, 42].